Project: A new take on cancer therapy: Developing inhibitors of activation induced cytidine deaminase (AID)
| Acronym | LEMONAID (Reference Number: 113873) |
| Duration | 01/04/2020 - 01/04/2023 |
| Project Topic | LEMONAID will deliver AIDIs, a new class of drugs that address cancer through prevention, by preventing cancer recurrence after treatment, and by preventing its initial occurrence from a healthy state. The drugs will be inhibitors of AID (activation induced cytidine deaminase), and in the first instance will be developed as an add-on drug to prevent cancer relapse in Diffuse Large B-Cell Lymphoma (DLBCL). At the end of LEMONAID, lead candidates will be ready to enter GLP-toxicity evaluation. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 12 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Cytura Therapeutics BV | Coordinator | Netherlands |
| 2 | InnoSer Belgie NV | Partner | Belgium |
| 3 | Microsynth AG | Partner | Switzerland |
| 4 | University of Oslo; Institute of Clinical Medicine | Partner | Norway |